Dostarlimab yields 80% complete response in mismatch repair-deficient rectal cancer, NEJM April 28—no surgery, radiation, chemo for 6 months in 103 patients, 100% cancer-free.
mRNA COVID vaccines within 100 days of checkpoint therapy double 3-year survival, ESMO 2025 MD Anderson—particularly in cold tumors low PD-L1, 5-fold boost.
Veiled vectors: 12 immunotherapy FDA approvals 2025, 28 total, bispecific antibodies bind cancer immune cells.
Economic dialectics: $400 billion digital health to $1,250 billion 2030 WEF, immunotherapy’s veiled veil transmutes tumor’s specter into survival’s enduring idyll.
This win’s subtle symphony unveils not response’s cadence, but treatment’s durable dance—veiled veils of 80% from dostarlimab, where science’s artistry yields reinvention’s radius in oncology’s majestic march.
